Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles by Lone Skov
Based on 113 articles published since 2008
||||

Between 2008 and 2019, L. Skov wrote the following 113 articles about Psoriasis.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5
1 Guideline Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. 2017

Raaby, Line / Zachariae, Claus / Østensen, Monika / Heickendorff, Lene / Thielsen, Peter / Grønbæk, Henning / Skov, Lone / Kyvsgaard, Nini / Madsen, Jakob T / Heidenheim, Michael / Funding, Anne T / Strauss, Gitte / Lindberg, Rune / Iversen, Lars. ·Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. ·Acta Derm Venereol · Pubmed #27958611.

ABSTRACT: Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.

2 Review [Comorbidity in connection with psoriasis is more than psoriatic arthritis]. 2018

Kvist-Hansen, Amanda / Kaiser, Hannah / Skov, Lone / Hansen, Peter Riis. ·prh@dadlnet.dk. ·Ugeskr Laeger · Pubmed #29368688.

ABSTRACT: Psoriasis is a common chronic inflammatory disease which is associated with extensive comorbidity, including psoriatic arthritis, cardiovascular and cardiometabolic disease, inflammatory bowel disease, malignancy, chronic kidney disease and depression. Clinical guidelines have been developed to target some of these comorbid diseases in patients with psoriasis and should be used by the treating physician.

3 Review Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. 2017

Cohen, A D / Wu, J J / Puig, L / Chimenti, S / Vender, R / Rajagopalan, M / Romiti, R / de la Cruz, C / Skov, L / Zachariae, C / Young, H S / Foley, P / van der Walt, J M / Naldi, L / Prens, E P / Blauvelt, A. ·Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. · Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel. · Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, U.S.A. · Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. · University of Rome Tor Vergata, Rome, Italy. · Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada. · Department of Dermatology, Apollo Hospitals, Chennai, India. · Department of Dermatology, University of São Paulo, São Paulo, Brazil. · Clínica Dermacross, Santiago, Chile. · Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. · The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K. · Department of Dermatology, Salford Royal NHS Foundation Trust, Manchester, U.K. · Skin & Cancer Foundation Inc., Carlton, Vic., Australia. · Department of Dermatology, The University of Melbourne, Melbourne, Vic., Australia. · St Vincent's Hospital, Melbourne, Vic., Australia. · International Psoriasis Council, St Louis, MO, U.S.A. · Department of Dermatology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. · Deptartment of Dermatology, Erasmus MC, P.O. Box 5201, 3008, AE Rotterdam, the Netherlands. · Oregon Medical Research Center, Portland, OR, U.S.A. ·Br J Dermatol · Pubmed #28646580.

ABSTRACT: The introduction of biological drugs for the treatment of patients with psoriasis has revolutionized treatment paradigms and enabled numerous patients to achieve disease control with an acceptable safety profile. However, the high cost of biologics limits access to these medications for the majority of patients worldwide. In recent years, the introduction of biosimilars for inflammatory diseases has become a fast evolving field. The future use of biosimilars offers the potential for decreased cost and increased access to biologics for patients with psoriasis. For approval of biosimilars, different regulatory agencies use highly variable methods for definition, production, approval, marketing and postmarketing surveillance. Due to potential interchangeability between biologics and biosimilars, traceability and pharmacovigilance are required to collect accurate data about adverse events in patients with psoriasis; spontaneous reporting, registries and use of 'big data' should facilitate this process on a global basis. The current article describes biosimilar regulatory guidelines and examples of biosimilar uptake in clinical practice in several countries around the world. As it is apparent that biological therapy treatment decisions may become more physician independent, the International Psoriasis Council recommends that dermatologists should take an active role in the development of biosimilar prescribing policies with their respective healthcare settings and government agencies.

4 Review Health-related Quality of Life in Children and Adolescents with Psoriasis: A Systematic Review and Meta-analysis. 2017

Randa, Hilde / Todberg, Tanja / Skov, Lone / Larsen, Lotte S / Zachariae, Robert. ·Unit of Psychooncology and Health Psychology, Department of Oncology, Aarhus University Hospital, DK-8000 Aarhus, Denmark. hilderanda@psy.au.dk. ·Acta Derm Venereol · Pubmed #27983745.

ABSTRACT: Studies demonstrating the negative impact of paediatric psoriasis on health-related quality of life (HRQOL) are accumulating, but little is known about moderators of HRQOL. The objectives of this review were to summarize studies on HRQOL in paediatric psoriasis and to explore the potential moderating influences of demographic and clinical variables. Searches were conducted by 2 independent researchers in PubMed, Embase, CINAHL, PsycINFO, and Scopus for papers published between 1995 (the date the first dermatology-specific HRQOL-instrument for children was introduced) and 2016. Eligible studies were required to report HRQOL data for children and/or adolescents with psoriasis (4-18 years) using validated HRQOL questionnaires. Seven-teen eligible studies (number of patients=1,185) were identified. Moderation analyses revealed that study samples with a higher percentage of girls were associated with better HRQOL (β = 0.19), while a higher mean age of onset (β = 0.83) and study quality (β = 0.28) were associated with lower HRQOL (all p<0.05). Several papers did not provide the information necessary for exploring between-study differences, thus the moderation analysis results should be interpreted with caution. In conclusion, children and adolescents with psoriasis experience moderate impairment of HRQOL. Certain demographic characteristics (e.g. sex) and clinical characteristics (e.g. age at onset) appear to moderate this impact.

5 Review Biosimilars for psoriasis: clinical studies to determine similarity. 2017

Blauvelt, A / Puig, L / Chimenti, S / Vender, R / Rajagopalan, M / Romiti, R / Skov, L / Zachariae, C / Young, H / Prens, E / Cohen, A / van der Walt, J / Wu, J J. ·Oregon Medical Research Center, Portland, OR, U.S.A. · Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. · University of Rome Tor Vergate, Rome, Italy. · Dermatrials Research Inc., Hamilton, ON, Canada. · Venderm Innovations in Psoriasis, Hamilton, ON, Canada. · Apollo Hospitals, Chennai, India. · Department of Dermatology, University of São Paulo, São Paulo, Brazil. · Herllev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. · Manchester Academic Health Science Centre, Department of Dermatology, University of Manchester, Salford Royal Hospital, Manchester, U.K. · Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. · Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. · Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel. · International Psoriasis Council, St Louis, MO, U.S.A. · Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, U.S.A. ·Br J Dermatol · Pubmed #27639072.

ABSTRACT: Biosimilars are drugs that are similar, but not identical, to originator biologics. Preclinical analytical studies are required to show similarity on a molecular and structural level, but efficacy and safety studies in humans are essential to determining biosimilarity. In this review, written by members of the International Psoriasis Council, we discuss how biosimilars are evaluated in a clinical setting, with emphasis on extrapolation of indication, interchangeability and optimal clinical trial design.

6 Review Co-morbidity in psoriasis: mechanisms and implications for treatment. 2017

Lønnberg, Ann Sophie / Skov, Lone. ·a Department of Dermato-Allergology, Herlev and Gentofte Hospital , University of Copenhagen , Hellerup , Denmark. ·Expert Rev Clin Immunol · Pubmed #27426230.

ABSTRACT: INTRODUCTION: Psoriasis is a common, chronic, immune-mediated inflammatory disorder. The disease is associated with several co-morbidities including cardiovascular disease, metabolic syndrome, and psychiatric disorders. It is important to identify and treat these co-morbidities because they have a strongly negative effect on the overall health of patients with psoriasis. Unfortunately, these co-morbidities are often overlooked and/or left untreated. Therefore, the aim of this review is to discuss the mechanisms of how co-morbidities are associated with psoriasis as well as implications for the clinic to be able to recognize such co-morbidities. Areas covered: This is a review of studies investigating and discussing co-morbidities of psoriasis and screening. Literature was retrieved by searching on the PubMed database using individual and combined search terms related to relevant co-morbidities. Expert commentary: Effective management of psoriasis involves targeting of both psoriasis and co-morbidities.

7 Review Psoriasis and Obesity. 2016

Jensen, Peter / Skov, Lone. ·Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark. ·Dermatology · Pubmed #28226326.

ABSTRACT: Psoriasis is a common chronic inflammatory skin disease with a complex pathogenesis consisting of a genetic component, immune dysfunction, and environmental factors. It is associated with numerous comorbidities including psoriatic arthritis, cardiovascular disease, metabolic syndrome, and obesity. Evidence suggests that obesity is a risk factor for incident psoriasis, aggravates existing psoriasis, and that weight reduction may improve the severity of psoriasis in overweight individuals. Excess body weight may interfere with the medical treatment used in psoriasis and adds to the cardiovascular risk profile in these patients, which underscores the importance of effective weight control regimens. In this review we examine the current literature with regard to the association between obesity and psoriasis.

8 Review Management of cardiovascular disease in patients with psoriasis. 2016

Egeberg, Alexander / Skov, Lone. ·a Department of Dermato-Allergology, Herlev and Gentofte Hospital , University of Copenhagen , Hellerup , Denmark. ·Expert Opin Pharmacother · Pubmed #27192114.

ABSTRACT: INTRODUCTION: Patients with psoriasis have an increased incidence and prevalence of cardiovascular (CV) risk factors, and CV undertreatment in these patients is a well-established problem. The link between psoriasis and CV disease is present on a pathogenic level, as well as due to modifiable lifestyle factors such as smoking and alcohol abuse. AREAS COVERED: In this manuscript we describe the evidence associating psoriasis with CV disease, as well as the pharmacological and non-pharmacological treatment of CV risk factors including the CV effects of anti-psoriatic therapy and vice versa. EXPERT OPINION: Current guidelines recommend that patients with psoriasis are screened for CV risk factors, and recommend smoking cessation, reduced alcohol consumption, altering of lifestyle to move to a normal-weight body-mass index, exercising 3 times a week for 30 minutes, and monitoring and modifying cholesterol levels, respectively. While the current sum of evidence is not sufficient to recommend specific therapies for psoriasis solely based on their potential CV impact, some guidelines have suggested a 1.5 multiplication factor, in patients with severe psoriasis, to the Framingham risk score. Indeed, the importance of screening for CV risk factors and strict adherence to established primary and secondary preventive measures in these patients should be emphasized.

9 Review Targeting IL-17 with ixekizumab in patients with psoriasis. 2015

Dyring-Andersen, Beatrice / Skov, Lone / Zachariae, Claus. ·Department of Dermato-Allergology, Herlev & Gentofte Hospital, Kildegaardsvej 28, DK-2900 Hellerup, Denmark. ·Immunotherapy · Pubmed #26569072.

ABSTRACT: Psoriasis is a multifactorial chronic inflammatory skin disease of unknown etiology. Knowledge of the pathophysiology of psoriasis has evolved and identified IL-17 as a key pro-inflammatory mediator in psoriasis creating new medical avenues. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of moderate-to-severe psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. The currently available Phase I to III data indicate that ixekizumab is a well-tolerated promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.

10 Review Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. 2015

Bangsgaard, Nannie / Rørbye, Christina / Skov, Lone. ·Herlev and Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, 2900, Hellerup, Denmark. Nannie.Bangsgaard@regionh.dk. · Department of Obstetrics and Gynecology, Hvidovre Hospital, University of Copenhagen, 2650, Hvidovre, Denmark. · Herlev and Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, 2900, Hellerup, Denmark. ·Am J Clin Dermatol · Pubmed #26149091.

ABSTRACT: Psoriasis is a chronic inflammatory disease with a well-documented negative effect on the quality of life of affected patients. Psoriasis often occurs in the reproductive years, during which the issue of pregnancy needs to be addressed. The course of psoriasis during pregnancy is unpredictable, and many patients face the challenge of needing treatment during pregnancy. In this review we provide an overview of the key considerations for managing psoriasis in pregnant women, covering the potential effects of active psoriasis and co-morbid conditions on the health of the mother and fetus, as well as the effects of psoriasis treatment options on the developing fetus. Although there are no robust data on the safety of systemic treatment of pregnant women, increasing evidence regarding the safety of cyclosporine (ciclosporin) treatment as well as anti-tumor necrosis factor-α is available and should be considered in pregnant women with moderate to severe psoriasis unresponsive to local corticosteroids and UVB light treatment.

11 Review Ixekizumab for treatment of psoriasis. 2015

Dyring-Andersen, Beatrice / Skov, Lone / Zachariae, Claus. ·Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Kildegaardsvej 28, DK-2900 Hellerup, Denmark. ·Expert Rev Clin Immunol · Pubmed #25748485.

ABSTRACT: Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.

12 Review miRNAs in inflammatory skin diseases and their clinical implications. 2015

Løvendorf, Marianne B / Skov, Lone. ·Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, 2900 Hellerup, Denmark. ·Expert Rev Clin Immunol · Pubmed #25719822.

ABSTRACT: miRNAs are a class of non-coding RNA molecules that modulate gene expression post-transcriptionally. They have a major impact on several physiological and pathological cellular processes including modulation of the innate and the adaptive immune system. The role of miRNAs in skin biology is still incomplete; however, it is known that miRNAs are implicated in various cellular processes of both normal and diseased skin. Some miRNAs appear to be consistently deregulated in several different inflammatory skin diseases, including psoriasis and atopic dermatitis, indicating a common role in fundamental biological processes. The clinical implications of miRNAs are intriguing, both from a diagnostic and a therapeutic perspective. Accordingly, there is emerging evidence for the clinical potential of miRNAs as both biomarkers and possible therapeutic targets in skin diseases. Future studies will hopefully establish the biological significance of miRNAs in skin biology, paving the way for new miRNA-based diagnostic and therapeutic applications in dermatology.

13 Review New drugs and treatment targets in psoriasis. 2015

Kofoed, Kristian / Skov, Lone / Zachariae, Claus. ·Department of Dermatovenereology, Copenhagen University Hospital, Bispebjerg, DK-2400 Copenhagen, Denmark. kkofoed@hotmail.com, kristian.kofoed@regionh.dk. ·Acta Derm Venereol · Pubmed #25111317.

ABSTRACT: In recent years, the increased understanding of the pathophysiology of psoriasis has resulted in several new treatments. The success of ustekinumab proved the importance of the IL-23/T helper cell 17 axis in psoriatic diseases. Several new biologics targeting this axis will reach the clinic in the next years. Biologics are costly, require injections, and some patients experience tacaphylaxis, thus, the development of orally available, small-molecule inhibitors is desirable. Among small-molecules under investigation are A3 adenosine receptor agonists, Janus kinase inhibitors, and phosphodiesterase inhibitors. We review published clinical trials, and conference abstracts presented during the last years, concerned with new drugs under development for the treatment of psoriasis. In conclusion, our psoriasis armamentarium will be filled with several new effective therapeutic options the coming years. We need to be aware of the limitations of drug safety data when selecting new novel treatments. Monitoring and clinical registries are still important tools.

14 Review [Psoriasis is associated with type 2 diabetes]. 2013

Gyldenløve, Mette / Knop, Filip Krag / Vilsbøll, Tina / Zachariae, Claus / Skov, Lone. ·Dermato-allergologisk Afdeling K, Gentofte Hospital, Niels Andersens Vej 65, 2900 Hellerup, Denmark. mette.gyldenloeve@regionh.dk ·Ugeskr Laeger · Pubmed #23462038.

ABSTRACT: Psoriasis is a chronic inflammatory skin disease with a global prevalence of 2-3%. In recent years it has been established that patients with psoriasis carry an increased risk of type 2 diabetes, but the underlying pathophysiological mechanisms remain unclear. The association is most likely due to a combination of shared genes, immunoinflammatory mechanisms and a number of diabetes risk factors in patients with psoriasis. The current review summarises the evidence in the field and calls for attention on diabetes risk assessment, preventive measures and treatment in patients with psoriasis.

15 Review [Psoriasis and atherothrombotic disease]. 2010

Ahlehoff, Ole / Gislason, Gunnar H / Skov, Lone / Hansen, Peter Riis. ·Kardiologisk Afdeling P, Gentofte Hospital, 2900 Hellerup, Denmark. ·Ugeskr Laeger · Pubmed #20654288.

ABSTRACT: Psoriasis and atherosclerosis share immunoinflammatory mechanisms and patients with psoriasis may carry an excess of cardiovascular risk factors (hypercholesterolemia, hypertension, obesity, metabolic syndrome, diabetes mellitus, smoking etc.) and increased risk of atherothrombotic disease. The current review summarises the available evidence in this area of research and calls for increased awareness of cardiovascular risk assessment and treatment in patients with psoriasis.

16 Review Systemic combination treatment for psoriasis: a review. 2010

Jensen, Peter / Skov, Lone / Zachariae, Claus. ·Department of Dermato-Allergology, Copenhagen University Hospital Gentofte, Denmark. peterj01@geh.regionh.dk ·Acta Derm Venereol · Pubmed #20574597.

ABSTRACT: Psoriasis is a chronic inflammatory skin disease, which affects approximately 2.6% of the population in Northern Europe and Scandinavia. In order to achieve disease control, combinations of systemic treatments are sometimes needed for variable time periods. However, no evidence-based guidelines exist for the use of systemic combination therapy. Therefore, our aim was to review the current literature on systemic anti-psoriatic combination regimens. We searched PubMed and identified 98 papers describing 116 studies (23 randomized) reporting on the effect of various systemic combination treatments. The most thoroughly investigated combination was retinoid and phototherapy. Further controlled research is needed to define the safest and most effective combination regimens.

17 Clinical Trial Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. 2018

Iversen, L / Eidsmo, L / Austad, J / de Rie, M / Osmancevic, A / Skov, L / Talme, T / Bachmann, I / van de Kerkhof, P / Stahle, M / Banerjee, R / Oliver, J / Fasth, A E R / Frueh, J. ·Aarhus University Hospital, Aarhus, Denmark. · Department of Dermatology, Karolinska University Hospital, Stockholm, Sweden. · Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. · Oslo University Hospital, Oslo, Norway. · Academisch Medisch Centrum, Amsterdam, The Netherlands. · Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden. · Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. · University of Bergen, Bergen, Norway. · Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. · Novartis Healthcare Private Limited, Hyderabad, India. · Novartis Pharma AG, Basel, Switzerland. · Novartis Sverige AB, Täby/Stockholm, Sweden. ·J Eur Acad Dermatol Venereol · Pubmed #29633373.

ABSTRACT: BACKGROUND: To date, biological treatments have been assessed in subjects with a long-term history of psoriasis and previous failures to systemic and topical therapies. In rheumatoid arthritis and other immune-mediated inflammatory diseases, early intensive systemic treatment prolongs treatment-free remission. We hypothesize that, by treating patients with psoriasis early with an effective systemic therapy, we may be able to alter the clinical outcome and the natural course of the disease. The STEPIn study (NCT03020199) investigates early intervention with secukinumab versus narrow-band ultraviolet B (nb-UVB) phototherapy in subjects with new-onset psoriasis. OBJECTIVE: To determine whether early intervention with either nb-UVB treatment or secukinumab in subjects with new-onset plaque psoriasis might modify the natural course of the disease. METHODS: One hundred and sixty subjects aged 18-50 years with new-onset (≤12 months) moderate-to-severe plaque psoriasis and naïve to systemic treatment and phototherapy will be randomized to secukinumab 300 mg or nb-UVB. The Main Study has two treatment arms: Arm A1, subcutaneous secukinumab 300 mg at baseline, Weeks 1, 2, 3 and 4, and every 4 weeks thereafter until and including Week 52; Arm B1, one/two cycles of nb-UVB for 12 weeks each (maximum 28-week break between cycles). After treatment discontinuation, patients will be followed up and monitored for disease activity up to Week 208. A Mechanistic Sub-study will assess immunological changes and pathogenic tissue-resident memory T cells in skin biopsies. CONCLUSIONS: STEPIn is the first study to investigate whether early intensive treatment in new-onset psoriasis can modify the long-term natural course of the disease and thus become a novel treatment strategy for patients with psoriasis.

18 Clinical Trial The Vitamin D Analogue Calcipotriol Reduces the Frequency of CD8+ IL-17+ T Cells in Psoriasis Lesions. 2015

Dyring-Andersen, B / Bonefeld, C M / Bzorek, M / Løvendorf, M B / Lauritsen, J P H / Skov, L / Geisler, C. ·Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. · Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. · Department of Clinical Pathology, Naestved Hospital, Naestved, Denmark. ·Scand J Immunol · Pubmed #25904071.

ABSTRACT: The vitamin D analogue calcipotriol is an immunomodulatory drug widely used to treat psoriasis; however, how calcipotriol affects the immune cells in psoriasis lesions is not fully understood. The aim of this study was to investigate the effect of calcipotriol on the frequency of CD4(+) and CD8(+) T cells and innate lymphoid cells (ILC) and their production of IL-17A, IFN-γ and IL-22 in psoriasis lesions in patients with chronic plaque psoriasis. Eighteen patients with psoriasis were included, and two similar psoriasis lesions were chosen for each patient. One lesion was treated with calcipotriol (50 μg/g) and the other with vehicle twice a day for 14 days. The clinical effect was measured by degree of erythema, scaling and induration in each lesion (SUM score). Skin biopsies were collected for histological and immunohistochemical analyses. Skin-derived cells were isolated and analysed by flow cytometry. After 14 days of treatment with calcipotriol, a significant clinical and histological effect was seen; however, we found no differences in the frequency of CD4(+) and CD8(+) T cells or ILC between calcipotriol- and vehicle-treated skin. The main finding was a significant decrease in CD8(+) IL-17(+) T cells in skin-derived cells from calcipotriol-treated skin, which was further supported by the absence of CD8(+) IL-17(+) T cells in immunohistochemical staining of calcipotriol-treated skin. No changes in the frequency of IL-22(+) or IFN-γ(+) cells were observed. Our findings show that the vitamin D analogue calcipotriol reduces the frequency of CD8(+) IL-17(+) T cells in psoriasis lesions concomitant with clinical improvement.

19 Article Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. 2019

Danielsen, Kjersti / Duvetorp, Albert / Iversen, Lars / Østergaard, Mikkel / Seifert, Oliver / Steinar Tveit, Kåre / Skov, Lone. ·Department of Dermatology, University Hospital of North Norway, NO-9038 Tromsø, Norway. kjerstidanielsen2007@hotmail.com. ·Acta Derm Venereol · Pubmed #30085329.

ABSTRACT: Optimal clinical management of psoriasis and psoriatic arthritis (PsA) Optimal clinical management of psoriasis and psoriatic arthritis (PsA) requires understanding of the impact on patients. The NORdic PAtient survey of Psoriasis and PsA (NORPAPP) aimed to obtain current data on disease prevalence and patient perceptions in Sweden, Denmark and Norway. Among 22,050 individuals questioned, the reported prevalence of psoriasis and/or PsA was 9.7% (5.7% physician-diagnosed plus 4.0% self-diagnosed only); prevalence was similar in Sweden (9.4%) and Denmark (9.2%) but significantly higher in Norway (11.9%). Of those reporting a physician's diagnosis, 74.6% reported psoriasis alone, 10.3% PsA alone and 15.1% both. Patients with PsA perceived their disease to be more severe than those with psoriasis; patients with PsA and psoriasis reported greater disease severity than those with each condition alone. Patient's perceptions of psoriasis severity correlated weakly (Spearman's rho 0.42) with clinical severity; both patient perceptions and clinical measures are important in the assessment and management of psoriasis.

20 Article Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis. 2018

Egeberg, Alexander / Skov, Lone / Zachariae, Claus / Gislason, Gunnar H / Thyssen, Jacob P / Mallbris, Lotus. ·Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark. alexander.egeberg@gmail.com, alexander.egeberg.02@regionh.dk. ·Acta Derm Venereol · Pubmed #29487945.

ABSTRACT: It is unclear whether psoriasis is a progressive disease that requires early aggressive intervention. This population-based study identified patients with psoriasis and psoriatic arthritis (PsA). Survival analysis and Kaplan-Meier life table techniques were used. The study comprised 10,011 psoriasis patients (severe n = 4,618), and 1,269 patients also had PsA. Incidence of PsA increased with duration of cutaneous symptoms (p = 0.0001). Psoriasis diagnosed before age 20 or 30 years, respectively, suggested a lower risk of PsA than psoriasis diagnosed after age 50 years, yet age at first cutaneous symptoms did not predict development of PsA. No clear association with disease severity was found. PsA incidence appeared stable with longer duration of psoriasis, but further data are needed to firmly establish the relationship with age of psoriasis onset.

21 Article Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. 2018

Loft, Nikolai Dyrberg / Skov, Lone / Rasmussen, Mads Kirchheiner / Gniadecki, Robert / Dam, Tomas Norman / Brandslund, Ivan / Hoffmann, Hans Jürgen / Andersen, Malene Rohr / Dessau, Ram Benny / Bergmann, Ann Christina / Andersen, Niels Møller / Abildtoft, Mikkel Kramme / Andersen, Paal Skytt / Hetland, Merete Lund / Glintborg, Bente / Bank, Steffen / Vogel, Ulla / Andersen, Vibeke. ·Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. · Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. · Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. · Dermatology Clinic, Nykoebing Falster, Denmark. · Department of Clinical Immunology and Biochemistry, Lillebaelt Hospital, Vejle, Denmark. · Institute of Clinical Medicine, Aarhus University, and Department of Respiratory Diseases and Allergy B, Aarhus University Hospital, Aarhus, Denmark. · Department of Clinical Biochemistry, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. · Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark. · Focused research unit for Molecular Diagnostic and Clinical Research, IRS-Center Soenderjylland, Hospital of Southern Jutland, Aabenraa, Denmark. · Zitelab Aps, Copenhagen, Denmark. · Department of Microbiology and Infection Control, Serum Institute, Copenhagen, Denmark. · Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. · The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark. · Department of Rheumatology, Herlev and Gentofte Hospital, Hellerup, Denmark. · National Research Centre for the Working Environment, Copenhagen, Denmark. · Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. · OPEN (Odense Patient data Explorative Network), University of Southern Denmark, Odense, Denmark. ·PLoS One · Pubmed #29389950.

ABSTRACT: BACKGROUND: Psoriasis (PsO) is a chronic inflammatory disease with predominantly cutaneous manifestations. Approximately one third of patients with PsO develop psoriatic arthritis (PsA), whereas the remaining proportion of patients has isolated cutaneous psoriasis (PsC). These two phenotypes share common immunology, but with different heredity that might in part be explained by genetic variables. METHODS: Using a candidate gene approach, we studied 53 single nucleotide polymorphisms (SNPs) in 37 genes that regulate inflammation. In total, we assessed 480 patients with PsO from DERMBIO, of whom 151 had PsC for 10 years or more (PsC10), 459 patients with PsA from DANBIO, and 795 healthy controls. Using logistic regression analysis, crude and adjusted for age and gender, we assessed associations between genetic variants and PsO, PsC10, and PsA, as well as associations between genetic variants and development of PsA in PsO. RESULTS: Eleven polymorphisms in 10 genes were nominally associated with PsO and/or PsC and/or PsA (P < 0.05). After correction for multiple testing with a false discovery rate of 5%, two SNPs remained significant: TNF (rs361525) was associated with PsO, PsC10, and PsA; and IL12B (rs6887695) was associated with PsO. CONCLUSION: Among a cohort of Danish patients with moderate-to-severe psoriasis, two SNPs in the IL12B and TNF genes were associated with susceptibility of psoriasis. None of the SNPs were specifically associated with isolated cutaneous psoriasis or psoriatic arthritis.

22 Article Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab. 2018

Hesselvig, Jeanette Halskou / Egeberg, Alexander / Loft, Nikolai Dyrberg / Zachariae, Claus / Kofoed, Kristian / Skov, Lone. ·Department of Dermatology and Allergy, Herlev and Gentofte University Hospital, University of Copenhagen, Kildegaardsvej 28, DK-2900 Hellerup, Denmark. jeanettehalskou@gmail.com. ·Acta Derm Venereol · Pubmed #29110019.

ABSTRACT: Monitoring of biological treatment efficacy for psoriasis is based on clinical evaluation and patient's quality of life. However, long-term correlation between Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) in real life has not been studied in patients treated with ustekinumab. All patients with psoriasis treated with ustekinumab at our department were included (n = 120) in this study. Correlation analyses between the change in PASI and DLQI and the individual subquestions in DLQI were performed using Spearman's rank correlation coefficient. A correlation value of 0.57 (p-value <0.001) and 0.45 (p-value < 0.001) between PASI and DLQI were found in the period baseline - 4 months and baseline - 12 months, respectively. In DLQI subquestions, the greatest association was found for the questions on "Symptoms and feelings". Objective improvements in the severity of psoriasis were weakly to moderately associated with improvements in quality of life in patients with psoriasis treated with ustekinumab.

23 Article Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. 2018

Egeberg, A / Ottosen, M B / Gniadecki, R / Broesby-Olsen, S / Dam, T N / Bryld, L E / Rasmussen, M K / Skov, L. ·Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. · Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. · Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark. · Skin Clinic, Nykøbing Falster, Denmark. · Department of Dermatology, Roskilde Hospital, Roskilde, Denmark. · Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. ·Br J Dermatol · Pubmed #29094341.

ABSTRACT: BACKGROUND: Real-life data on newer biological and biosimilar agents for moderate-to-severe psoriasis are lacking. OBJECTIVES: To examine safety, efficacy and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab and ustekinumab) and compare originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima). METHODS: The DERMBIO registry contains data on all Danish patients with moderate-to-severe plaque psoriasis treated with biologics. We examined patients treated between 1 January 2007 and 31 March 2017. We used Kaplan-Meier survival curves and Cox regression to examine drug survival patterns. RESULTS: A total of 3495 treatment series (2161 patients) were included (adalimumab n = 1332; etanercept n = 579; infliximab n = 333; ustekinumab n = 1055 and secukinumab n = 196). Secukinumab had the highest number of PASI 100 (100% improvement from baseline Psoriasis Area and Severity Index) respondents, but also the lowest drug survival among all the biologics. Ustekinumab had the highest drug survival overall. There were no significant differences in discontinuation risk between originator and biosimilar versions of infliximab or etanercept. Treatment with higher than approved dosages was frequent for all drugs except for adalimumab and secukinumab. Adverse events (predominantly infections) were most frequent for secukinumab compared with the other agents. CONCLUSIONS: Ustekinumab was associated with the highest drug survival, and secukinumab with the lowest, although most patients on secukinumab were non-naïve. Switching from originator to biosimilar had no significant impact on drug survival, and the safety profiles were comparable. Adverse events occurred most frequently with secukinumab. Future studies are warranted to assess the long-term safety of novel biologics for psoriasis.

24 Article Risk of uncommon cancers in patients with psoriasis: a Danish nationwide cohort study. 2018

Jensen, P / Egeberg, A / Gislason, G / Thyssen, J P / Skov, L. ·Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. · Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. · Danish Heart Foundation, Copenhagen K, Denmark. · The National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark. ·J Eur Acad Dermatol Venereol · Pubmed #28960478.

ABSTRACT: BACKGROUND: Cancer-associated mortality is increased in psoriasis. However, little is known about the risk of less common cancers. OBJECTIVE: We aimed to evaluate the risk of less common cancers in patients with psoriasis compared to persons without psoriasis using a nationwide cohort study. METHODS: Between 1 January 2008 and 31 December 2012, we identified all Danish patients with a first-time hospital diagnosis of a less common cancer defined as <100 new cases/year/100.000 persons in Denmark. The primary endpoint was the occurrence of a diagnosis of cancer. RESULTS: We included 4 361 869 individuals. Of these, 58 138 were classified as having psoriasis. After adjusting for age, sex, socio-economic status and healthcare consumption, we found significantly elevated hazard ratios for cancers of bone and cartilage (HR 4.97 [2.32-10.62], P < 0.0001) in patients with psoriasis on systemic treatment. CONCLUSION: We provide further evidence of an increased cancer of bone and cartilage risk in patients with psoriasis.

25 Article Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. 2018

Loft, N D / Skov, L / Iversen, L / Gniadecki, R / Dam, T N / Brandslund, I / Hoffmann, H J / Andersen, M R / Dessau, R B / Bergmann, A C / Andersen, N M / Andersen, P S / Bank, S / Vogel, U / Andersen, V. ·Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. · Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. · Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. · Skin Clinic, Nykoebing Falster, Denmark. · Department of Clinical Immunology and Biochemistry, Lillebaelt Hospital, Vejle, Denmark. · Institute of Clinical Medicine, Aarhus University, and Department of Respiratory Diseases and Allergy B, Aarhus University Hospital, Aarhus, Denmark. · Department of Clinical Biochemistry, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. · Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark. · Focused Research Unit for Molecular Diagnostic and Clinical Research, IRS-Center Soenderjylland, Laboratory Center, Hospital of Southern Jutland, Aabenraa, Denmark. · Department of Microbiology and Infection Control, Serum Institute, Copenhagen, Denmark. · National Research Centre for the Working Environment, Copenhagen, Denmark. · Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. · OPEN (Odense Patient data Explorative Network), University of Southern Denmark, Odense, Denmark. ·Pharmacogenomics J · Pubmed #28696418.

ABSTRACT: Biological agents including anti-tumor necrosis factor (anti-TNF; adalimumab, infliximab, etanercept) and anti-interleukin-12/13 (IL12/23; ustekinumab) are essential for treatment of patients with severe psoriasis. However, a significant proportion of the patients do not respond to a specific treatment. Pharmacogenetics might be a way to predict treatment response. Using a candidate gene approach, 62 mainly functional single-nucleotide polymorphisms (SNPs) in 44 different genes were evaluated in 478 Danish patients with psoriasis undergoing 376 series of anti-TNF treatment and 230 series of ustekinumab treatment. Associations between genetic variants and treatment outcomes (drug survival and Psoriasis Area Severity Index reduction) were assessed using logistic regression analyses (crude and adjusted for gender, age, psoriatic arthritis and previous treatment). After correction for multiple testing controlling the false discovery rate, six SNPs (IL1B (rs1143623, rs1143627), LY96 (rs11465996), TLR2 (rs11938228, rs4696480) and TLR9 (rs352139)) were associated with response to anti-TNF treatment and 4 SNPs (IL1B (rs1143623, rs1143627), TIRAP (rs8177374) and TLR5 (rs5744174)) were associated with response to ustekinumab treatment (q<0.20). The results suggest that genetic variants related to increased IL-1β levels may be unfavorable when treating psoriasis with either anti-TNF or ustekinumab, whereas genetic variants related to high interferon-γ levels may be favorable when treating psoriasis with ustekinumab.

Next